Cephalon, Inc., today announced that the U.S. Food and Drug Administration has approved TREANDA® for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

[News Source]